CJC-1295 with DAC is defined by one deliberate innovation: a Drug Affinity Complex (DAC) appended to a stabilized GHRH backbone so the molecule binds circulating albumin and persists dramatically longer than earlier analogs like CJC-1295 without DAC. Its development represents a turning point in how researchers approached the problem of extending peptide half-life.
The half-life problem
Native growth-hormone-releasing hormone is cleared from circulation within minutes, degraded by dipeptidyl peptidase and filtered by the kidneys. For laboratories seeking to study sustained GHRH-receptor engagement rather than brief pulses, this rapid clearance was a fundamental obstacle that shorter analogs only partially solved.
From short fragment to long-acting analog
Peptide chemists had already learned to armor the GHRH(1-29) fragment against enzymatic degradation with targeted residue substitutions. Adding an albumin-binding element was the next conceptual step — it turned a minutes-scale signal into one that lingered for days, reshaping how the growth-hormone axis could be studied in model systems.
The role of albumin binding
Serum albumin is one of the most abundant and longest-lived proteins in plasma. By latching a reactive maleimide onto a free thiol on this carrier, the DAC-bearing peptide effectively hitchhikes on albumin's slow turnover, resisting clearance — the structural basis of its mechanism of action. This design principle of exploiting endogenous carrier proteins later reappeared across the wider peptide field.
A distinct identity within the GHRH family
Although it shares receptor biology with releasing-hormone tools such as sermorelin, the DAC form carved out a separate niche as the long-acting reference point, distinct from both sermorelin and the pulsatile no-DAC analog.
Legacy in research
The DAC concept made CJC-1295 an enduring reference for extended-action GHRH studies and a common comparator when new sustained-release strategies are evaluated. More context is in the CJC-1295 (DAC) research overview, and the chemistry behind the linker is detailed in its structure and synthesis article.
What the name came to signify
As the molecule entered the research vocabulary, “CJC-1295” became closely associated with the albumin-binding design, even though related stabilized GHRH analogs without the affinity complex are also discussed under similar naming conventions. That ambiguity makes structural specification important in historical and experimental writing. A DAC-bearing material and a no-DAC analog may activate the same receptor, but they are not interchangeable research reagents: one was developed to prolong systemic exposure, while the other retains a short-duration profile. The distinction preserves the central lesson of the development program—that pharmacokinetic engineering can alter an experiment without changing the receptor-facing pharmacophore.
Product page: CJC-1295 (DAC) research vials.
Research Use Only. Supplied strictly for laboratory research and development — not for human or veterinary use, consumption, or any therapeutic or diagnostic purpose. This article is research education, not usage guidance.